December 5, 2016 08:33 AM EST
R&D

Cere­cor blast­ed as its sec­ond clin­i­cal roll of the dice in days comes up snake eyes

John Carroll

Editor & Founder

Just a few days af­ter Cere­cor was pum­meled $CERC by the news that its lead de­pres­sion drug, CERC-301, failed a mid-stage study, the mi­cro­cap …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

A service from the Financial Times